Wolverine

Wolverine is a research blend combining BPC-157 (5 mg) and TB-500 (5 mg), for a nominal total of 10 mg, supplied as a single lyophilized research preparation. BPC-157 is a synthetic gastric pentadecapeptide studied in preclinical models of tissue repair, mucosal integrity, and angiogenic signaling; its mechanism is not fully characterized. TB-500 is a synthetic fragment of thymosin beta-4 studied for actin regulation, cell migration, and tissue-repair signaling in preclinical and in-vitro models. Evidence distinction: published research describes BPC-157 and TB-500 individually in preclinical (in-vitro and animal) settings. No published clinical evidence establishes efficacy of the combined Wolverine formulation itself, and evidence for the individual constituents should not be taken as evidence for the blend. Evidence level: preclinical. Findings from laboratory and animal studies should not be interpreted as established clinical benefits in humans. Neither BPC-157 nor TB-500 is approved by the FDA for any indication. Research use only; not for human consumption or therapeutic use.